RNLX (Renalytix AI) חוב לטווח קצר להון

Renalytix Plc (RNLX) organizes the rapid transport of biomaterials for kidney analysis, ensuring high efficiency for clinics. The company's price chart on the GURU.Markets platform, where the metric stands at 0.00, illustrates a period of aggressive cost optimization and a search for a buyer for biotech assets due to a lack of funds. Meanwhile, the business develops nephrological risk assessment systems, the profitability of which will increase once tests are integrated into medical standards.

While the trend of short-term debt to equity for Renalytix Plc (RNLX) remains stable, allowing the company to mitigate financial risks during complex negotiations with insurance companies regarding KidneyIntelX coverage. The ratio calculating current liabilities to equity confirms high solvency, although a conservative approach to borrowing limits the pace of aggressive business expansion.